5NW1
pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclobutanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (ligand 18)
Summary for 5NW1
Entry DOI | 10.2210/pdb5nw1/pdb |
Descriptor | Elongin-B, Elongin-C, Von Hippel-Lindau disease tumor suppressor, ... (5 entities in total) |
Functional Keywords | protein complex, ubiquitin ligase, hypoxia inducible factor, ligase |
Biological source | Homo sapiens (Human) More |
Cellular location | Nucleus : Q15370 Q15369 Isoform 1: Cytoplasm. Isoform 3: Cytoplasm: P40337 |
Total number of polymer chains | 12 |
Total formula weight | 168999.70 |
Authors | Gadd, M.S.,Soares, P.,Ciulli, A. (deposition date: 2017-05-04, release date: 2017-09-20, Last modification date: 2024-01-17) |
Primary citation | Soares, P.,Gadd, M.S.,Frost, J.,Galdeano, C.,Ellis, L.,Epemolu, O.,Rocha, S.,Read, K.D.,Ciulli, A. Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). J. Med. Chem., 61:599-618, 2018 Cited by PubMed: 28853884DOI: 10.1021/acs.jmedchem.7b00675 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.1 Å) |
Structure validation
Download full validation report![Download](/newweb/media/icons/dl.png)
![Download](/newweb/media/icons/dl.png)